The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation
Abstract Dabigatran interferes with many coagulation tests. To overcome this obstacle the use of idarucizumab as an in vitro antidote to dabigatran has been proposed. The aim of this study was to test the effect of idarucizumab as an in vitro antidote to dabigatran in ex vivo plasma samples from rou...
Guardado en:
Autores principales: | Mojca Božič Mijovski, Rickard E. Malmström, Nina Vene, Jovan P. Antovic, Alenka Mavri |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a25cf96b94804dc3a82f82c18ba9f6e4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation
por: Alenka Mavri, et al.
Publicado: (2021) -
Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis.
por: Wilma Potze, et al.
Publicado: (2014) -
Role of a thrombin generation assay in the prediction of infection severity
por: Boaz Elad, et al.
Publicado: (2021) -
Prognostic value of thrombin generation parameters in hospitalized COVID-19 patients
por: María Eugenia de la Morena-Barrio, et al.
Publicado: (2021) -
Idarucizumab for dabigatran reversal in cardiac tamponade complicating percutaneous intervention
in ST elevation myocardial infarction
por: Marta Kurdziel, et al.
Publicado: (2021)